Prior to this role, Robin was Executive Director at CV Therapeutics (CVT) Europe, where he was responsible for establishing the European office for CV Therapeutics.
At CVT he was also responsible for spearheading the strategic development and launch of a range of specialist cardiovascular products and identifying and establishing CVT European marketing partnerships before CVT was acquired by Gilead Sciences in 2009.
With a pharmaceutical career history spanning over two decades, Robin brings a wealth of knowledge and experience to Actelion UK from several managerial roles, which include Head of Cardiovascular Marketing at Sanofi-Synthélabo UK and Marketing Director within Bayer’s Global Strategic Marketing Group.
Robin commented: “This role attracted me from the very outset and I am privileged to have the opportunity to lead the UK team of such an innovative global pharmaceutical company. I look forward to supporting Actelion’s continued commitment to these important therapy areas, to the specialist physicians, healthcare professionals and patient group communities.”
Actelion Pharmaceuticals is committed to researching and developing treatments for rare orphan diseases in areas of high unmet clinical need, such as pulmonary arterial hypertension, Gaucher’s and Niemann-Pick type C. The company’s first drug, Tracleer, has been approved as a therapy for pulmonary arterial hypertension in patients with functional class III in the UK.